Dr. Marty Makary has stepped down as FDA Commissioner after weeks of mounting pressure over his opposition to the Trump administration's decision to approve flavored vapes. The agency's top food safety official will assume the role.
Makary's resignation follows his private disagreement with the administration over vape flavoring policy. He had internally opposed the approval of flavored vaping products, creating friction between his scientific position and the administration's regulatory direction. The tension became public enough that sources close to the situation revealed his reservations about the decision.
This departure marks a significant shift in FDA leadership at a time when the agency faces competing pressures around tobacco regulation, public health policy, and industry interests. The vape flavoring decision itself remains contentious among health researchers and pediatricians, who have long raised concerns about flavored nicotine products' appeal to young people.
The FDA historically serves as a counterbalance to commercial interests through its regulatory authority over drugs, medical devices, and tobacco products. Makary's exit suggests that maintaining scientific independence within the agency remains difficult when leadership priorities diverge from administration policy.
His successor, drawn from the agency's food safety division, will inherit an FDA navigating complex questions about emerging products, regulatory standards, and the administration's approach to public health oversight. The transition underscores ongoing debates about how much weight FDA commissioners should give to independent scientific review versus political direction.
The vaping industry continues to push for expanded access to flavored products, arguing that adult consumers should have choices. Public health advocates counter that flavored vapes drive youth addiction to nicotine at rates that have rebounded in recent years after declining earlier in the decade.